59 reports of this reaction
6.5% of all BUTENAFINE HYDROCHLORIDE reports
#2 most reported adverse reaction
OFF LABEL USE is the #2 most commonly reported adverse reaction for BUTENAFINE HYDROCHLORIDE, manufactured by Bayer Healthcare LLC.. There are 59 FDA adverse event reports linking BUTENAFINE HYDROCHLORIDE to OFF LABEL USE. This represents approximately 6.5% of all 901 adverse event reports for this drug.
Patients taking BUTENAFINE HYDROCHLORIDE who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among BUTENAFINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for BUTENAFINE HYDROCHLORIDE:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 59 FDA reports for BUTENAFINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 6.5% of all adverse event reports for BUTENAFINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience off label use while taking BUTENAFINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.